Literature DB >> 28110992

Idarucizumab for the Reversal of Dabigatran.

Michael Gottlieb1, Basem Khishfe2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28110992     DOI: 10.1016/j.annemergmed.2016.11.025

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


× No keyword cloud information.
  3 in total

Review 1.  Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs.

Authors:  Ipek Celikyurt; Christoph R Meier; Michael Kühne; Beat Schaer
Journal:  Drug Saf       Date:  2017-11       Impact factor: 5.606

Review 2.  Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations.

Authors:  Jens Lutz; Kerstin Jurk; Helmut Schinzel
Journal:  Int J Nephrol Renovasc Dis       Date:  2017-06-12

3.  Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma.

Authors:  Gail Edwards; Cristina Roman; Rondhir Jithoo; Biswadev Mitra
Journal:  Trauma Case Rep       Date:  2017-12-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.